Oncology On targeted radiotherapeutics, with Marc Hedrick Dr Marc Hedrick, president and CEO of Plus Therapeutics, discusses developing targeted radiotherapeutics.
News AZ/BenevolentAI collab achieves AI-enabled further milestone... Two additional novel AI-generated targets for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF) have been discovered using the Benevolent Platform and selected for AstraZ
News Lundbeck preps for key bexicaserin data around year-end Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth hopes.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
